BR112012017188A2 - composto agonista de mgluz, sua composição farmacêutica e seu uso - Google Patents

composto agonista de mgluz, sua composição farmacêutica e seu uso

Info

Publication number
BR112012017188A2
BR112012017188A2 BR112012017188A BR112012017188A BR112012017188A2 BR 112012017188 A2 BR112012017188 A2 BR 112012017188A2 BR 112012017188 A BR112012017188 A BR 112012017188A BR 112012017188 A BR112012017188 A BR 112012017188A BR 112012017188 A2 BR112012017188 A2 BR 112012017188A2
Authority
BR
Brazil
Prior art keywords
mgluz
pharmaceutical composition
agonist compound
agonists
mglu2
Prior art date
Application number
BR112012017188A
Other languages
English (en)
Other versions
BR112012017188B1 (pt
BR112012017188A8 (pt
Inventor
James Allen Monn
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012017188(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112012017188A2 publication Critical patent/BR112012017188A2/pt
Publication of BR112012017188A8 publication Critical patent/BR112012017188A8/pt
Publication of BR112012017188B1 publication Critical patent/BR112012017188B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

patente de invenção: "agonistas de mglu2". a presente invenção refere-se a novos agonistas de mglu2 úteis no tratamento de distúrbios bipolar, esquizofrenia, depressão e distúrbio de ansiedade generalizada. os novos agonistas são representados pela fórmula
BR112012017188-7A 2009-12-21 2010-12-15 Agonistas de glutamato metabotrópico (mglu2), e composição farmacêutica BR112012017188B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382290.6 2009-12-21
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17
US61/305,239 2010-02-17
PCT/US2010/060371 WO2011084437A1 (en) 2009-12-21 2010-12-15 Mglu2 agonists

Publications (3)

Publication Number Publication Date
BR112012017188A2 true BR112012017188A2 (pt) 2016-03-22
BR112012017188A8 BR112012017188A8 (pt) 2016-10-04
BR112012017188B1 BR112012017188B1 (pt) 2021-06-22

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017188-7A BR112012017188B1 (pt) 2009-12-21 2010-12-15 Agonistas de glutamato metabotrópico (mglu2), e composição farmacêutica

Country Status (35)

Country Link
US (1) US8318184B2 (pt)
EP (1) EP2516406B1 (pt)
JP (1) JP5779190B2 (pt)
KR (1) KR101395356B1 (pt)
CN (1) CN102695701B (pt)
AR (1) AR079343A1 (pt)
AU (1) AU2010340039B2 (pt)
BR (1) BR112012017188B1 (pt)
CA (1) CA2784667C (pt)
CR (1) CR20120322A (pt)
CY (1) CY1114880T1 (pt)
DK (1) DK2516406T3 (pt)
DO (1) DOP2012000173A (pt)
EA (1) EA020229B1 (pt)
EC (1) ECSP12011989A (pt)
ES (1) ES2435651T3 (pt)
HK (1) HK1171228A1 (pt)
HN (1) HN2012001160A (pt)
HR (1) HRP20131052T1 (pt)
IL (1) IL220011A (pt)
JO (1) JO2978B1 (pt)
MA (1) MA33824B1 (pt)
MX (1) MX2012007332A (pt)
MY (1) MY160618A (pt)
NZ (1) NZ600305A (pt)
PE (1) PE20121688A1 (pt)
PL (1) PL2516406T3 (pt)
PT (1) PT2516406E (pt)
RS (1) RS53063B (pt)
SG (1) SG181836A1 (pt)
SI (1) SI2516406T1 (pt)
TN (1) TN2012000281A1 (pt)
TW (1) TWI477490B (pt)
UA (1) UA107684C2 (pt)
WO (1) WO2011084437A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183304A1 (en) 2010-02-17 2012-09-27 Takeda Pharmaceutical Heterocyclic compound
TWI520935B (zh) * 2010-11-18 2016-02-11 美國禮來大藥廠 作為ｍＧｌｕＲ２／３拮抗劑之４－經取代－３－苯基磺醯基甲基－雙環［３.１.０］己烷化合物
BR112013012384A2 (pt) * 2010-11-18 2019-09-24 Lilly Co Eli compostos 3-benzilóóxi-biciclo[3.1.0]hexano 4-substituídos como antagonistas receptores de mglu2 e mglu3
EA023553B1 (ru) * 2011-06-17 2016-06-30 Эли Лилли Энд Компани Агонисты рецептора mglu2
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
EA201891617A3 (ru) * 2014-01-21 2019-04-30 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
WO2002055485A1 (en) * 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
HUP0400620A3 (en) * 2001-01-11 2012-09-28 Lilly Co Eli Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
BR0311558A (pt) * 2002-06-11 2007-04-27 Lilly Co Eli composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
TWI520935B (zh) * 2010-11-18 2016-02-11 美國禮來大藥廠 作為ｍＧｌｕＲ２／３拮抗劑之４－經取代－３－苯基磺醯基甲基－雙環［３.１.０］己烷化合物
BR112013012384A2 (pt) * 2010-11-18 2019-09-24 Lilly Co Eli compostos 3-benzilóóxi-biciclo[3.1.0]hexano 4-substituídos como antagonistas receptores de mglu2 e mglu3

Also Published As

Publication number Publication date
PE20121688A1 (es) 2012-12-05
EP2516406B1 (en) 2013-09-18
BR112012017188B1 (pt) 2021-06-22
KR20120094056A (ko) 2012-08-23
JP2013514974A (ja) 2013-05-02
SI2516406T1 (sl) 2013-11-29
PL2516406T3 (pl) 2014-03-31
DOP2012000173A (es) 2012-11-30
HK1171228A1 (en) 2013-03-22
AU2010340039B2 (en) 2014-03-20
PT2516406E (pt) 2013-10-10
IL220011A (en) 2014-03-31
JO2978B1 (en) 2016-03-15
TN2012000281A1 (en) 2013-12-12
CR20120322A (es) 2012-07-10
MX2012007332A (es) 2012-07-20
AR079343A1 (es) 2012-01-18
SG181836A1 (en) 2012-08-30
HN2012001160A (es) 2015-08-24
US8318184B2 (en) 2012-11-27
HRP20131052T1 (hr) 2013-12-06
TWI477490B (zh) 2015-03-21
DK2516406T3 (da) 2013-10-14
TW201144290A (en) 2011-12-16
JP5779190B2 (ja) 2015-09-16
MY160618A (en) 2017-03-15
EA201290558A1 (ru) 2012-12-28
CN102695701A (zh) 2012-09-26
ES2435651T3 (es) 2013-12-20
CA2784667C (en) 2014-11-18
CY1114880T1 (el) 2016-12-14
IL220011A0 (en) 2012-07-31
CA2784667A1 (en) 2011-07-14
AU2010340039A1 (en) 2012-08-09
RS53063B (en) 2014-04-30
WO2011084437A1 (en) 2011-07-14
CN102695701B (zh) 2014-10-01
EP2516406A1 (en) 2012-10-31
ECSP12011989A (es) 2012-07-31
KR101395356B1 (ko) 2014-05-14
US20110152334A1 (en) 2011-06-23
NZ600305A (en) 2014-01-31
UA107684C2 (xx) 2015-02-10
EA020229B1 (ru) 2014-09-30
BR112012017188A8 (pt) 2016-10-04
MA33824B1 (fr) 2012-12-03

Similar Documents

Publication Publication Date Title
BR112012017188A8 (pt) composto agonista de mglu2, sua composição farmacêutica e seu uso
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
BR112015012425A2 (pt) composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
BRPI0913457A2 (pt) "composto, composição farmacêutica, e, uso do composto"
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
BR112014032809A2 (pt) melhora de autofagia ou aumento de longevidade pela administração de urolitinas ou precursores das mesmas
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
EA201100503A1 (ru) Глюкозидные производные и их применения
DE602008000754D1 (de) Tropanverbindungen
CL2007001784A1 (es) Compuestos derivados de benzoxazol de formula la, su composicion farmaceutica, metodo para medir in vivo depositos de amoloide empleando dicha composicion, y uso del compuesto la para preparar un medicamento, y compuesto de formula ib, y su uso como precursor en la preparacion de un compuesto marcado.
BR112012007322A2 (pt) composto de 2-piridona usados como inibidores de neutrófilo elastase
CR11814A (es) Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
ECSP099806A (es) Oxazolidinonas sustituidas y su uso
BR112015004529A8 (pt) alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende
ATE500222T1 (de) Benzamid- und heteroarenderivate als cetp- inhibitoren
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112015004523A2 (pt) compostos de tetraciclina
SG158091A1 (en) Imidazoazepinone compounds
BRPI0918629B8 (pt) sal de n-[6-cis-2,6-dimetilmorfolin-4-il]piridina-3-il]-2-metil-4'-(trifluormetóxi)[1-1'-bifenil]-3-carboxamida, e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.